#United States #Houston #epigenetics #BIRD #Zoghbi

Recognition for Pioneering Researchers

In a significant recognition of their transformative work in the field of epigenetics, Dr. Huda Zoghbi and Dr. Adrian Bird have been awarded the prestigious 2026 Louisa Gross Horwitz Prize from Columbia University. This award celebrates their groundbreaking contributions to understanding the epigenetic regulation of the nervous system and its implications for human neurological diseases, specifically Rett syndrome.

Dr. Zoghbi serves as the founding director of the Duncan Neurological Research Institute at Texas Children's Hospital and is a distinguished professor at Baylor College of Medicine. Dr. Bird is a prominent professor at the University of Edinburgh, and their collaboration has led to remarkable advancements in medical science.

The Impact of Rett Syndrome

Rett syndrome, primarily affecting girls, is a severe neurodevelopmental disorder that can profoundly impair speech, mobility, and fundamental bodily functions. Prior to the groundbreaking work of Zoghbi and Bird, Rett syndrome was considered poorly understood and untreatable. Their research has changed the narrative surrounding this condition, offering hope and a path forward for those affected. Thanks to their findings, individuals with Rett syndrome can now live into adulthood with proper support.

In 1999, Dr. Zoghbi identified mutations in the MeCP2 gene as a direct cause of Rett syndrome, establishing the crucial link between epigenetics and neurological disorders. She demonstrated that balanced levels of MeCP2 are essential for the normal functioning of neurons, revealing that insufficient MeCP2 leads to the onset of Rett syndrome, while excessive levels result in neurological complications. This discovery paved the way for genetic testing to detect the disorder early.

On the other hand, Dr. Bird elucidated key principles of epigenetic regulation. His research in the 1980s brought to light the existence of CpG islands, which are specialized DNA clusters that play a crucial role in gene expression. His work further identified the MeCP2 protein, which responds to chemical tags on the DNA, acting as a regulatory mechanism for gene activity.

Therapeutic Possibilities

Zoghbi and Bird's research not only reshaped the understanding of Rett syndrome but also opened doors to potential therapies. They found that the effects caused by abnormal levels of MeCP2 could be reversible. For instance, Bird's laboratory developed the first mouse model for Rett syndrome. Remarkably, in 2007, they demonstrated that reactivating the MeCP2 protein in these mice significantly improved neurological symptoms. Further, Zoghbi's research indicated that administering oligonucleotide therapy can reverse the effects of incorrect MeCP2 functionality in mice.

This pioneering work has led to the development of new therapeutic approaches, such as gene replacement drugs (TSHA-102 and NGN-401) and RNA-regulating treatments (ION 440), which are currently making strides in clinical development, offering hope for a future cure.

Laura Landweber, chair of Columbia's Horwitz Prize committee, praised their joint efforts, emphasizing the significant impact of their findings on both scientific understanding and patient care. Henry Colecraft, another committee member, expressed that their collaborative research has imparted renewed hope to families impacted by devastating neurological disorders.

This award not only honors Zoghbi and Bird as the 122nd and 123rd recipients of the Horwitz Prize, but also aligns their achievements with numerous past laureates who later won Nobel Prizes, highlighting their contributions to the field of medicine and science.

About Texas Children's Hospital

Texas Children's Hospital, a nonprofit healthcare organization known for its commitment to improving pediatric and women's health, has consistently ranked as one of the best children's hospitals in the nation. It integrates research and clinical practice, including the pioneering work done at the Duncan Neurological Research Institute. The organization's mission encompasses improving health outcomes for children globally through advances in patient care and innovative research.